Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 3031185 in Healthy Subjects
NCT06916702Phase 1Suspended
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2025
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3031185 (7 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-Emergent Adverse Events. Started Apr 2025; status: suspended.
02
Drugs
BI 3031185
Beyond the preview
Go deeper on NCT06916702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916702.